Suppr超能文献

BRCA1/2 相关乳腺癌化疗后行输卵管卵巢切除术时偶然发现隐匿性妇科癌行辅助化疗和知情显微镜检查的价值:病例报告。

Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.

机构信息

Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan.

Department of Clinical Genetics, St. Marianna University School of Medicine, Kawasaki-shi, Japan.

出版信息

Jpn J Clin Oncol. 2021 Mar 3;51(3):492-497. doi: 10.1093/jjco/hyaa239.

Abstract

BRCA1/2 mutation carriers are at high risk for type II ovarian, fallopian tube or peritoneal cancer. Although risk-reducing salpingo-oophorectomy plays an important role in the prevention of these BRCA1/2-associated gynecological cancers, occult ovarian, fallopian tube, or peritoneal cancer is discovered upon risk-reducing salpingo-oophorectomy in 1-4% of BRCA1/2 mutation carriers. Notably, around 30% of BRCA1/2 mutation carriers who undergo risk-reducing salpingo-oophorectomy have undergone adjuvant chemotherapy for breast cancer. We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer. During subsequent risk-reducing salpingo-oophorectomy, a 5.5-mm nodule was observed at the edge of the left fimbria. Microscopic examination of the tumour tissue revealed high-grade serous carcinoma with degenerate tumour cells and fibrosis. Peritoneal fluid was negative for cancer cells. Two months later, hysterectomy, omentectomy and retroperitoneal lymphadenectomy were performed. The final diagnosis was stage FIGO IA fallopian tube cancer. Adjuvant chemotherapy (TC administered every 3 weeks) was applied, and there has been no evidence of recurrence for 5 years. In applying gynecologic surgery and adjuvant chemotherapy, we followed the general recommendation for stage IA fallopian tube cancer. There is no standard strategy for the treatment of occult fallopian tube cancer detected after chemotherapy for BRCA1-associated triple-negative breast cancer. According to our experience in this case, we believe the clinical value of staging laparotomy in cases of a small occult BRCA1/2-associated gynecological cancer should be further investigated.

摘要

BRCA1/2 突变携带者患 II 型卵巢、输卵管或腹膜癌的风险很高。尽管降低风险的输卵管卵巢切除术在预防这些与 BRCA1/2 相关的妇科癌症方面发挥着重要作用,但在 1-4%的 BRCA1/2 突变携带者中,在降低风险的输卵管卵巢切除术中发现隐匿性卵巢、输卵管或腹膜癌。值得注意的是,大约 30%接受降低风险的输卵管卵巢切除术的 BRCA1/2 突变携带者已经接受了乳腺癌的辅助化疗。我们描述了一位 BRCA1 突变携带者在接受新辅助紫杉醇加卡铂(TC)化疗治疗三阴性乳腺癌后不久,在左侧输卵管伞端边缘发现隐匿性癌症的发现和治疗。在随后的降低风险的输卵管卵巢切除术中,在左侧输卵管伞端边缘观察到一个 5.5 毫米的结节。肿瘤组织的显微镜检查显示高级别浆液性癌,伴有退化的肿瘤细胞和纤维化。腹腔液中未发现癌细胞。两个月后,进行了子宫切除术、网膜切除术和腹膜后淋巴结切除术。最终诊断为 FIGO 分期 IA 输卵管癌。应用了辅助化疗(每 3 周给予 TC),5 年来无复发迹象。在应用妇科手术和辅助化疗时,我们遵循了 IA 期输卵管癌的一般建议。对于 BRCA1 相关三阴性乳腺癌化疗后发现的隐匿性输卵管癌,尚无标准的治疗策略。根据我们在这种情况下的经验,我们认为在隐匿性 BRCA1/2 相关妇科癌症较小的情况下,分期剖腹术的临床价值应进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验